[
  {
    "ts": "2025-10-17T16:23:44+00:00",
    "headline": "3 S&P 500 Stocks We Find Risky",
    "summary": "The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.",
    "url": "https://finance.yahoo.com/news/3-p-500-stocks-risky-162344228.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "0f0c51fa-7cbb-3d27-b479-2bcc4928d822",
      "content": {
        "id": "0f0c51fa-7cbb-3d27-b479-2bcc4928d822",
        "contentType": "STORY",
        "title": "3 S&P 500 Stocks We Find Risky",
        "description": "",
        "summary": "The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.",
        "pubDate": "2025-10-17T16:23:44Z",
        "displayTime": "2025-10-17T16:23:44Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/38789a008ce226609c06f366fc9e7eea",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "WMT Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kyBt9AOSdalSOEpzReBRiA--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/38789a008ce226609c06f366fc9e7eea.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/wfBHrMa7u5AnN4_ovetPtQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/38789a008ce226609c06f366fc9e7eea.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/3-p-500-stocks-risky-162344228.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/3-p-500-stocks-risky-162344228.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            },
            {
              "symbol": "CELG-RT"
            },
            {
              "symbol": "DGX"
            },
            {
              "symbol": "WMT"
            },
            {
              "symbol": "^SPX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-17T14:00:00+00:00",
    "headline": "SystImmune, Inc. and Bristol Myers Squibb Announce First Global Phase I Results of Iza-bren, an EGFR x HER3 Bispecific Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors at ESMO 2025",
    "summary": "SystImmune Inc. (SystImmune), a clinical-stage biotechnology company, and Bristol Myers Squibb (NYSE: BMY) today announced the oral presentation of the first disclosure of the safety and efficacy data from the global phase I US-Lung-101 study (NCT05983432) of iza-bren (BL-B01D1), a potentially first-in-class EGFR x HER3 bispecific antibody-drug conjugate (ADC), at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany. Iza-bren is jointly developed by SystImmune and Br",
    "url": "https://finance.yahoo.com/news/systimmune-inc-bristol-myers-squibb-140000134.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "44905818-0363-3bef-9d0c-d509e42c44d2",
      "content": {
        "id": "44905818-0363-3bef-9d0c-d509e42c44d2",
        "contentType": "STORY",
        "title": "SystImmune, Inc. and Bristol Myers Squibb Announce First Global Phase I Results of Iza-bren, an EGFR x HER3 Bispecific Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors at ESMO 2025",
        "description": "",
        "summary": "SystImmune Inc. (SystImmune), a clinical-stage biotechnology company, and Bristol Myers Squibb (NYSE: BMY) today announced the oral presentation of the first disclosure of the safety and efficacy data from the global phase I US-Lung-101 study (NCT05983432) of iza-bren (BL-B01D1), a potentially first-in-class EGFR x HER3 bispecific antibody-drug conjugate (ADC), at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germany. Iza-bren is jointly developed by SystImmune and Br",
        "pubDate": "2025-10-17T14:00:00Z",
        "displayTime": "2025-10-17T14:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/a2c51215c5ec63b757111724cd5e99fd",
          "originalWidth": 400,
          "originalHeight": 200,
          "caption": "(PRNewsfoto/SystImmune Inc.)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9O6MLWScjve8x12UaJ5fdQ--~B/aD0yMDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/a2c51215c5ec63b757111724cd5e99fd.cf.webp",
              "width": 400,
              "height": 200,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/w3IY14xgSYxhxZXyRr5iJA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/a2c51215c5ec63b757111724cd5e99fd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/systimmune-inc-bristol-myers-squibb-140000134.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/systimmune-inc-bristol-myers-squibb-140000134.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CELG-RT"
            },
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-17T11:00:00+00:00",
    "headline": "Bristol Myers Squibb Foundation Awards Grant to PATH to Improve Care for Inherited Blood Disorders in India",
    "summary": "New initiative aims to build capacity in high-prevalence areas to increase screening and prevention of hemoglobinopathies NORTHAMPTON, MA / ACCESS Newswire / October 17, 2025 /PATH has launched a groundbreaking initiative to address the rising burden ...",
    "url": "https://finance.yahoo.com/news/bristol-myers-squibb-foundation-awards-110000487.html",
    "source": "ACCESS Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "59d5a41f-80cd-3508-a70e-9ddf39f0cdeb",
      "content": {
        "id": "59d5a41f-80cd-3508-a70e-9ddf39f0cdeb",
        "contentType": "STORY",
        "title": "Bristol Myers Squibb Foundation Awards Grant to PATH to Improve Care for Inherited Blood Disorders in India",
        "description": "",
        "summary": "New initiative aims to build capacity in high-prevalence areas to increase screening and prevention of hemoglobinopathies NORTHAMPTON, MA / ACCESS Newswire / October 17, 2025 /PATH has launched a groundbreaking initiative to address the rising burden ...",
        "pubDate": "2025-10-17T11:00:00Z",
        "displayTime": "2025-10-17T11:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/accesswire.ca/037691495b6a21914f44ff9e80e694e5",
          "originalWidth": 1280,
          "originalHeight": 850,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/PBM_POq7GJWNWU6FrCWHwQ--~B/aD04NTA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/accesswire.ca/037691495b6a21914f44ff9e80e694e5.cf.webp",
              "width": 1280,
              "height": 850,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/OwcWBFPNW8stzDKHeazWTw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/037691495b6a21914f44ff9e80e694e5.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "ACCESS Newswire",
          "url": "https://www.accessnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-squibb-foundation-awards-110000487.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-squibb-foundation-awards-110000487.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            },
            {
              "symbol": "CELG-RT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-17T11:00:00+00:00",
    "headline": "In the Wake of Bristol Myers' $1.5B Business Acquisition, LegalMatch.com Emphasizes the Need for Expert Legal Guidance in Mergers",
    "summary": "LegalMatch Highlight Critical Legal Considerations in Major Business Mergers and Acquisitions RENO, NEVADA / ACCESS Newswire / October 17, 2025 / Following the recent $1.5 billion acquisition of privately held Orbital Therapeutics by Bristol Myers ...",
    "url": "https://finance.yahoo.com/news/wake-bristol-myers-1-5b-110000486.html",
    "source": "ACCESS Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "3e505332-9b33-3d9d-b97b-a6f6172dcdf6",
      "content": {
        "id": "3e505332-9b33-3d9d-b97b-a6f6172dcdf6",
        "contentType": "STORY",
        "title": "In the Wake of Bristol Myers' $1.5B Business Acquisition, LegalMatch.com Emphasizes the Need for Expert Legal Guidance in Mergers",
        "description": "",
        "summary": "LegalMatch Highlight Critical Legal Considerations in Major Business Mergers and Acquisitions RENO, NEVADA / ACCESS Newswire / October 17, 2025 / Following the recent $1.5 billion acquisition of privately held Orbital Therapeutics by Bristol Myers ...",
        "pubDate": "2025-10-17T11:00:00Z",
        "displayTime": "2025-10-17T11:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "ACCESS Newswire",
          "url": "https://www.accessnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/wake-bristol-myers-1-5b-110000486.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/wake-bristol-myers-1-5b-110000486.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]